Redhill Biopharma (NASDAQ:RDHL) Shares Pass Below 200 Day Moving Average – Should You Sell?

by · The Cerbat Gem

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.56 and traded as low as $1.17. Redhill Biopharma shares last traded at $1.18, with a volume of 20,363 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Redhill Biopharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on Redhill Biopharma

Redhill Biopharma Trading Up 2.6%

The business has a 50 day moving average of $1.27 and a 200-day moving average of $1.56. The stock has a market cap of $5.36 million, a PE ratio of 0.00 and a beta of 4.83.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Redhill Biopharma stock. Gagnon Securities LLC bought a new position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned approximately 0.54% of Redhill Biopharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.

Featured Articles